Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Processa Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −1 vs. Q4 2021
- Shares held
- 1.07M
- −249.7K (−18.9%) vs. Q4 2021
- Total value
- $3.22M
- −$3.25M (−50.2%) vs. Q4 2021
- New holders
- 2
- 3 more added
- Sold out
- 3
- 3 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PCSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $498.3K |
| Q1 2026 | 10 | $448.5K |
| Q4 2025 | 10 | $331.0K |
| Q3 2025 | 14 | $341.9K |
| Q2 2025 | 13 | $75.9K |
| Q1 2025 | 9 | $63.2K |
| Q4 2024 | 8 | $87.5K |
| Q3 2024 | 8 | $66.5K |
| Q2 2024 | 9 | $101.0K |
| Q1 2024 | 11 | $251.5K |
| Q4 2023 | 18 | $376.5K |
| Q3 2023 | 20 | $349.8K |
| Q2 2023 | 19 | $691.4K |
| Q1 2023 | 22 | $852.6K |
| Q4 2022 | 18 | $1.28M |
| Q3 2022 | 18 | $2.58M |
| Q2 2022 | 18 | $3.24M |
| Q1 2022 | 18 | $3.22M |
| Q4 2021 | 19 | $6.47M |
| Q3 2021 | 18 | $12.2M |
| Q2 2021 | 18 | $11.2M |
| Q1 2021 | 17 | $12.3M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Processa Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 373,598 | $1.13M | 0.00% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 303,703 | $915.0K | 0.33% | 00.0% | Unchanged |
| Worth Venture Partners, LLC | 70,954 | $214.0K | 0.10% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 64,902 | $195.0K | 0.00% | 00.0% | Unchanged |
| Verdence Capital Advisors LLC | 59,884 | $180.0K | 0.02% | −3,343−5.3% | Reduced |
| Janney Montgomery Scott LLC | 46,231 | $139.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 41,486 | $125.0K | 0.00% | 00.0% | Unchanged |
| Coastal Bridge Advisors, LLC | 32,500 | $98.0K | 0.02% | 00.0% | Unchanged |
| BlackRock Inc. | 29,088 | $87.0K | 0.00% | −1,413−4.6% | Reduced |
| Solas Capital Management, LLC | 22,844 | $69.0K | 0.04% | −173,306−88.4% | Reduced |
| Northern Trust Corp | 15,401 | $46.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,134 | $9.00K | 0.00% | +1,521+94.3% | Added |
| Wells Fargo & Company | 3,139 | $9.00K | 0.00% | +3,076+4,882.5% | Added |
| Allworth Financial LP | 1,700 | $5.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1,000 | $3.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,115 | $3.00K | 0.00% | +897+411.5% | Added |
| Morgan Stanley | 1 | $0 | 0.00% | +1 | New |
| Whittier Trust Co | 22 | $0 | 0.00% | +22 | New |
| Essex Investment Management Co LLC | 0 | $0 | 0.00% | −73,180−100.0% | Sold out |
| Vectors Research Management, LLC | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −7−100.0% | Sold out |